EC closes procedural case against Servier

29 January 2012

The European Commission said last Friday that it has closed an investigation into Fremch independent drugmaker Laboratoires Servier for suspected provision of misleading and incorrect information to the Commission's pharmaceuticals sector inquiry.

In 2010, the Commission addressed statements of objections to Les Laboratoires Servier and Servier SAS, taking the provisional view that they had provided misleading and incorrect information in reply to a request for information in the context of the pharmaceutical sector inquiry. In its reply to the statement of objections Servier put forward various arguments as to why the information it supplied was neither misleading nor incorrect.

In light of Servier's arguments which would require significant further investigation, the Commission has decided to close the case, and instead focus on the substantive enforcement of competition rules in a number of pending cases, including one involving Servier.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics